Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 145

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 145
---
 performed or supported many important corporate functions for us. Our consolidated financial statements for the fiscal years ended December 31, 2023, 2022 and 2021 reflect charges for these services on an allocation basis. As a result, such consolidated financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento during such periods. We have incurred significant costs to replace the services and resources that are no longer provided by Sorrento. We are also incurring additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. As we now operate separately from Sorrento, if we are not able to maintain adequate systems and business functions, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. Risks Related to Ownership of our Common Stock The market price of our Common Stock may fluctuate significantly, and investors in our Common Stock may lose all or a part of their investment. The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. For example, from November 11, 2022 (the first trading day following the closing of the Business Combination) to May 5, 2025, our closing stock price ranged from $3.99 to $518.00. The market price of our Common Stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:

| • |     | our ability to commercialize ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved; |

| • |     | legal disputes or other developments relating to proprietary rights, including patents, litigation matters and                                                                                                                             
 our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; |

87

| • |     | extension of the lock-up restriction by court order in the Chapter 11                                                                                                                            
 Cases (as defined below) on the 76,000,000 shares (on a pre-